Hospira receives FDA approval

LAKE FOREST - Hospira Inc., a generic injectable pharmaceuticals company, announced it received U.S. Food and Drug Administration approval for a 500 mg vial of azithromycin for injection in the ADD-Vantage System. The anti-infective medication is a generic version of Pfizer's Zithromax for injection. U.S. sales of generic and name-brand azithromycin for injection were approximately $40 million in 2008. ADD-Vantage is a specially designed, two-part system that does not require clinicians to use a needle and syringe to mix the drug and the solution. This reduces the risk of accidental needlesticks, enhances work flow and can result in less waste due to stability and shelf-life factors.